Molecular Therapy for Disk Degeneration and Pain

Fackson Mwale

1 Division of Orthopaedic Surgery, McGill University, Lady Davis Institute for Medical Research, Montreal, Quebec, Canada

Global Spine J 2013;3:185–192.

Address for correspondence Fackson Mwale, PhD, Division of Orthopaedic Surgery, McGill University, Lady Davis Institute for Medical Research, 3755 Chemin de la Cote Ste-Catherine, Montreal, Quebec H3T 1E2, Canada (e-mail: fmwale@ldi.jgh.mcgill.ca).

Abstract

The nucleus pulposus of the intervertebral disk contains high amounts of the proteoglycan aggrecan, which confers the disk with a remarkable ability to resist compression. Other molecules such as collagens and noncollagenous proteins in the extracellular matrix are also essential for function. During disk degeneration, aggrecan and other molecules are lost due to proteolysis. This can result in loss of disk height, which can ultimately lead to pain. Biological therapy of intervertebral disk degeneration aims at preventing or restoring primarily aggrecan content and other molecules using therapeutic molecules. The purpose of the article is to review recent advances in biological repair of degenerate disks and pain.

Keywords
- intervertebral disk degeneration
- Link N
- biological repair
- growth factor
- pain

Normal Disk Function

It is possible to bend and twist the spine while resisting compression from gravity and muscle action because of the IVDs. They are formed of the peripheral collagen-rich annulus fibrosus (AF) surrounding the proteoglycan-rich central nucleus pulposus (NP), sandwiched between cartilaginous end plates (→ Fig. 1). The function of the disk is to resist compression and permit limited movements in which loading forces are spread evenly on the vertebral bodies. The AF consists primarily of collagen type I fibers and is responsible for resisting tensile forces, and the NP consists mainly of loosely assembled collagen type II fibers and proteoglycan, mostly aggrecan. The cell density in the human adult NP is \(4 \times 10^6\) cells/cm\(^3\), and the AF has \(9 \times 10^6\) cells/cm\(^3\), which is very low when compared with other tissues such as cartilage. Most of the disk nutrition is through the cartilage end plates, but with age the vascularity decreases and the end plates become calcified, which limit the disk’s nutrient supply.

Thus a sparse number of cells maintain homeostasis in an abundant extracellular matrix (ECM) by balancing synthesis and degradation (→ Fig. 2). This is orchestrated through complex anabolic (bone morphogenetic proteins [BMPs], transforming growth factor-β [TGF-β], and insulin-like growth factor [IGF]) and catabolic (matrix metalloproteinases, aggrecanases, and inflammatory cytokines like interleukin 1 [IL-1] and tumor necrosis factor-α [TNF-α]) processes, in addition to tissue inhibitors of matrix metalloproteinases (TIMPs), which control catabolic activities. The adult disk is the largest avascular tissue in the body, which is a major determinant of its metabolic functions. The main route for disk nutrition is through the cartilaginous end plate and is adapted to anaerobic metabolism because of a low oxygen tension. This results in high concentrations of lactic acid and low pH, conditions that are not conducive to high levels of protein synthesis required during tissue repair or regeneration. It is possible that an authentic disk cell might be the only cell capable of functioning under these adverse conditions.
Aging and Disk Degeneration

Mechanisms that contribute to degenerative changes in the disk include reduction in nutrient supply, diminished cell viability, loss of notochordal cells, genetics, cell senescence, and loading history. These lead to biochemical alterations in composition and structure of the ECM due to both depleted synthesis and increased degradation, with aggrecan being particularly susceptible to proteolytic damage and loss. Aging of the IVD is associated with increased degeneration. The disk has no endogenous repair activity. However, induced repair of disk tissue may be possible, as chymopapain treatment to degrade the degenerate NP stimulates new matrix formation, although not consistently.

During disk degeneration, the NP changes from a gelatinous structure to a more fibrous texture as fissures appear in the NP and the AF. The proteoglycan-to-collagen ratio (measured as GAG-to-hydroxyproline ratio) is highest in patients with grade 2 disks (~23:1) and lowest in those with Thomson grade 4 disks (~5:1). In healthy juveniles (2 to 5 years old), the GAG-to-hydroxyproline ratio in the NP is ~25:1. Similarly, in young adult disk with no degeneration (15 to 25 years), the GAG-to-hydroxyproline ratio within the NP is ~27:1. With increasing age there is a marked drop in the GAG-to-hydroxyproline ratio, which declines to ~5:1 in the elderly (60 to 80 years). These processes may be the results of a marked reduction of nutritional supply, due to regression of blood vessels and calcification of the end plates.

The focus of molecular therapy is to restore the juvenile disk composition to degenerative disks by stimulating the production of proteoglycan and other matrix components. This article reviews the research on using molecular therapy to treat disk degeneration and subsequently pain.

Molecular Therapy

Concepts in Tissue Engineering of IVD

There is growing evidence that laboratory-grown tissues or organs can be used to support the function of defective or injured body parts, and these tissue-engineering procedures have recently been applied to the disk. Such advances in
regenerative medicine have led to promising new approaches for the biological treatment of disk degeneration. Disk repair can be facilitated by the injection of growth factors, cell supplementation, gene therapy, and the introduction of biomaterials. Several recent investigations showed in rabbit models or in cell culture models of differentiation that it may be possible to use mesenchymal stem cells for IVD repair and regeneration, avoiding the need to harvest autologous disk cells.\textsuperscript{20,21}

**Growth Factors**

Growth factors are usually polypeptides that are involved in stimulation and maintenance of the integrity of the disk ECM. Typically, they bind to receptors resulting in signaling cascades between cells and communicate their effects through endocrine, paracrine, and autocrine mechanisms. The endocrine signaling mechanism involves the release of a growth factor from a specialized group of cells in the kidney, liver, heart, or other organs into the circulation and acting on a distant target tissue. In a paracrine mechanism, growth factor communication occurs between neighboring cells that have specific receptors within a tissue or organ. Autocrine signals, on the other hand, are those in which a growth factor acts on the same cell, and an intracrine signal is produced by growth factor acting within the same cell.

Growth factors, such as IGFs, TGF-\(\beta\), epidermal growth factors (EGFs), and fibroblast growth factor (FGF), are known to stimulate new disk matrix formation (\textsuperscript{\textbullet} Fig. 3).\textsuperscript{22,23} Other therapeutic molecules, such as anticyclics (TIMP-1 and TIMP-2) and intracellular regulators (Smad proteins, Sox 9), are being used (reviewed by Yoon and Patel\textsuperscript{24}; \textsuperscript{\textbullet} Fig. 4).

![Fig. 3](image)

**Fig. 3** Therapeutic molecules used in disk repair: transforming growth factor (TGF), bone morphogenetic protein (BMP), growth differentiation factor (GDF), cartilage-derived morphogenetic protein (CDMP), Sma-Mad (Smad) proteins, Sox 9, LIM mineralization protein-1 (LMP-1), tissue inhibitor of matrix metalloproteinase (TIMP), insulin-like growth factor-1 (IGF-1), platelet-derived growth factor-1 (PDGF), epidermal growth factor (EGF), fibroblast growth factor (FGF), and Link N.

**Insulin-Like Growth Factors**

IGFs (IGF-1 and IGF-2) are polypeptides whose sequence is similar to insulin, and IGFs bind their receptors, IGF1R and IGF2R, forming a complex system termed the IGF axis. IGF-1 controls matrix synthesis and mitotic activity. It stimulated proteoglycan synthesis in cells of the bovine NP.\textsuperscript{25} Further, Osada et al demonstrated the expression of IGF-1 mRNA and IGF-1 in cultured bovine IVD cells and proposed an autocrine/paracrine loop in the IVD. The effect of various growth factors on protein and proteoglycan synthesis on canine disk cells was dependent on the region of the disk from where the cells were derived.\textsuperscript{22} TGF-\(\beta\)1 and EGF produced better responses than FGF, and IGF-1 had no effect on cells from the AF.\textsuperscript{22} However, IGF-1 increased proteoglycan synthesis in monolayer cultures of bovine disk cells.\textsuperscript{11} In rat disks, during the late stages of aging, IGF-1 receptors are downregulated in addition to an increase in IGF binding proteins, leading to a decreased IGF-1 response.\textsuperscript{26} In a free-swelling explant culture model, IGF-1 produced marginal synthetic response in the NP and none in the AF.\textsuperscript{27}

**Fibroblast Growth Factor**

There are 22 members of the FGF family in humans. Although FGF-1 is acidic, FGF-2 is basic and is the most studied. FGFs from 1 to 10 all bind to FGF receptors. Others such as FGF11 to FGF14 do not, and apart from possessing similar sequence homology, they function differently to the FGFs. FGF-3 receptors are expressed in disk cells.\textsuperscript{28} Adding FGF-2 during culture expansion of NP cells in monolayer was found to sustain a differentiated cell phenotype by maintaining responsiveness to TGF-\(\beta\).\textsuperscript{29} However, FGF-1 supplementation to degenerated murine caudal disks had little or no effect on aggrecan and type II collagen mRNA expression.\textsuperscript{30} The authors concluded that AF cells in degenerated disks are responsive to some growth factors like TGF-\(\beta\) and not others in vivo.

**Epidermal Growth Factor**

EGF is a low-molecular-weight polypeptide that stimulates cell proliferation, growth, and differentiation of cells by binding to its receptor and stimulating protein tyrosine kinase activity. As discussed previously, EGF stimulated proteoglycan synthesis in the organ culture of dog IVD tissues.\textsuperscript{31}

**TGF-\(\beta\) Superfamily**

All immune cell lineages, including B cells, T cells, and dendritic cells as well as macrophages, secrete TGF-\(\beta\), which negatively regulates their proliferation, differentiation, and activation by other cytokines. Thus, TGF-\(\beta\) is a potent immunosuppressant, and perturbation of TGF-\(\beta\) signaling is linked to autoimmunity, inflammation, and cancer.\textsuperscript{32} TGF-\(\beta\) pathway starts at the GS domain where TGF-\(\beta\) is activated and the ligand binding to the type II receptor (TGF-\(\beta\)RII) leads to recruitment of type I receptor (TGF-\(\beta\)RI). Then it phosphorylates the SMAD2 and SMAD3 family of signal transducers.\textsuperscript{33} With SMAD4 they form hetero-oligomeric complexes (also phosphorylation) and translocate to the nucleus, where they interact at the promoter with other transcription factors at
DNA sequence-specific binding. TGF-β regulates cell proliferation and ECM synthesis. TGF-β is stored in a latent form and very little is active. Disk cell proliferation and proteoglycan synthesis is stimulated by several growth factors that including TGF-β, IGF-1, platelet-derived growth factor, BMP-2, EGF, and BMP-7, also referred to as OP-1. These data suggest that using growth factors or growth factor genes may improve the success of a cellular approach to disk tissue engineering.

Bone Morphogenetic Proteins
BMPs were originally discovered by their ability to induce the formation of bone and cartilage, and the BMP pathway is paramount in the development of the dorsoventral axis in both vertebrates and invertebrates. Like TGF-β, BMPs are normally present in low amounts in healthy disk where they play a role in repair and maintenance of disk integrity. The receptors of BMP-2 and -4 were first found in hyaline cartilaginous cells within the end plate of young mice. The important functioning of BMP signals in disk degeneration was suggested by the fact that with age these BMPs and their receptors moved to the annulus and to the calcified cartilage at the site of enthesis. Recombinant BMP-2 can stimulate proteoglycan synthesis without expression of osteogenic phenotype intervertebral disk cells. Others have found that TGF-β and BMP-2 can induced disk calcification. Finally, LMP-1 can stimulate proteoglycan synthesis through its action on BMP. BMP pathway consists of BMP dimers binding to a membrane complex composed of BMP receptors 1 and 2 (serine/threonine kinases). Regulatory Smad1/Smad5 through phosphorylation with Smad 4 (co-Smad) form a Smad1/5 complex that enters the nucleus. Inside, the nucleus regulates gene expression after it associates with transcription factors. Nakase et al reported the localization of transcripts for BMP-4, -6, and growth differentiation factor-5 as well as BMP receptors in the outer layer of the anterior global spine journal vol. 3 no. 3/2013 molecular therapy for disk degeneration and pain mwale
annulus at an early stage of experimental cervical spondylosis, suggesting that BMPs are involved in chondrogenesis in spondylosis. Recombinant human BMP-7 (OP-1), a member of the TGF-β family of proteins, stimulated the synthesis of proteoglycans and collagens when added to rabbit disk cells cultured in alginate beads, after depletion of the matrix by IL-1 or chondroitinase ABC. To expand on these in vitro findings, the effects of BMP-7 were determined in vivo in a rabbit model of intervertebral disk degeneration. BMP-7 injection increased proteoglycan and collagen content in the disk, reversing the decrease in disk height, which led to restoration of the biomechanical properties. These studies showed that BMP-7 could promote repair in disk degeneration.

N-Terminus of Link Protein as an Endogenous Growth Factor

Human articular cartilage aging is associated with proteolytic degradation of its constituent proteoglycan aggregates. Link protein is found in aggregcan/hyaluronan aggregates, where it stabilizes the interaction between the two. The peptide DHLSDNYTLDHRAIH (Link N), cleaved by stromelysin from the N-terminus of the Link protein, can act as a growth factor and stimulate synthesis of proteoglycans and collagens in articular cartilage. Link N is conserved between rabbits and humans. It could represent an endogenous growth factor in the disk as it can stimulate the synthesis of both proteoglycan and collagen by disk cells in vitro, increase proteoglycan levels in vivo in a rabbit model of disk degeneration, and down-regulate hypertrophic and osteogenic differentiation of human mesenchymal stem cells. We also showed that the effects of this peptide could last for 12 weeks in the rabbit and for more than a week in human explant cultures. We have recently shown that Link N activates Smad1/5 signaling similar to that used by BMPs. Thus, Link N could represent a potential growth factor able to stimulate the production of an NP-like phenotype.

Gene Therapy

One of the limitations of growth factors is that they have short half-lives, transiently increasing matrix synthesis. Thus, a method is needed that can provide sustained growth factor concentrations within the IVD. Gene therapy offers that potential as it can direct a target cell to synthesize a desired substance by delivering a corresponding DNA or RNA using a viral or nonviral vector. Viral vectors and biocompatible materials, such as cationic liposomes, DNA–ligand complexes, and gene gun techniques, have been developed as vehicles to introduce potentially therapeutic genes into mammalian cells. Weholing et al first demonstrated gene transfer to the IVD. Later, the efficacy of cDNA for TGF-β, sox9, LIM mineralization protein-1, and TIMP to upregulate synthesis of matrix into the disk was shown. However, gene therapy, although very promising for the treatment of disk degeneration, is still in its infancy.

Wnt Signaling

Wnt/b-catenin (hereafter called Wnt) signaling is involved in development, degeneration, and regeneration of the IVD. The signaling cascade is initiated at the cell membrane by interaction between Wnt and the Frizzled receptors plus LRP5/6 co-receptors and is not depending on phosphorylation. Canonical Wnt signaling stabilizes cytoplasmic β-catenin and its translocation into the nucleus, to regulate expression of Wnt-target genes. Noncanonical Wnt signaling is independent of β-catenin signaling. They involve the activation of protein kinase C, calmodulin-dependent kinase II, and c-Jun N-terminal kinase. Wnt signaling has also been associated with degenerative joint disease. Wnt signaling suppresses proliferation of NP cells and induces cell senescence of the IVDs. Upregulation of matrix metalloproteinases by Wnt signaling causes dedifferentiation of NP cells, promoting cellular senescence and possibly leading to IVD degeneration. Members of the TGF-β superfamily and Wnt signaling cascades have been shown to physically interact in different tissues, suggesting new targets for therapy.

Pain and Innervations

Mechanisms of Axial Low Back Pain

Although disk degeneration does not necessarily correlate with actual pain, disk degeneration can be found in most patients suffering from back pain. Axial low back pain is characterized by spontaneous or movement-evoked pain or soreness. It is confined to the spine and low back region and can be induced by disk degeneration. IVDs have a sensory component that normally penetrates only the outer layers of the disk. In patients with chronic low back pain, increased nerve fibers and blood vessels that express substance P into the AF and even penetrating the NP were observed, which may be facilitated due to the loss of aggrecan and hydrostatic pressure. Nociceptive nerve ingrowth into painful IVD is linked with nerve growth factor production by blood vessels growing into the IVDs, from adjacent vertebral bodies. which can be upregulated in disk cells by the proinflammatory cytokines IL-1β and TNF-α.
produces increased spinal nerve root excitability and hypersensitivity to painful stimuli. Annular tears during disk degeneration can therefore release its contents and lead to nerve fiber irritation and back pain. Disk herniation can also result in compression of spinal nerve roots or dorsal root ganglia neurons.

**Pain Receptors**

Pain receptors are found on nerve endings located in the disk. Sensory fibers and their endings in the outer AF of lumbar intervertebral disks were first demonstrated in a rat. The AF of the human intervertebral disk is sparsely innervated, with substance P localized on the endothelium of small blood vessels in the AF of disks removed during anterior fusion for back pain. Once there is a pain stimulus, which may be due to tissue damage, activation of pain receptors takes place, releasing neurotransmitters that send information to the spinal cord and the brain. This process of pain transmission is called nociception and the pain receptors are called nociceptors. NK1 receptors through which vascular effects are mediated were found on vessels in the AF, suggesting a role for substance P in discogenic pain. Mechanoreceptors and nociceptors have been documented in the spine, and they are more extensive in degenerated disks where nerve fibers were found in the anterior longitudinal ligament and in the outer region of the disk. Apart from substance P-immunoreactive nerve fibers found in the anterior longitudinal ligament and the outer zone of the AF, fibers were also found in the inner parts of the disk. Finally, pain is an extremely complex process. Identification of the receptors and processes that are involved in the transmission of pain should lead to improved therapeutics in pain management.

**Conclusion**

Current biological repair approaches are exploring a combination of molecular, cellular, and tissue-engineering techniques to restore the integrity of the intervertebral disk or at least retard the further degeneration of NP. The target cohort of patients is dependent on the stage of disk degeneration. During early degeneration, when the AF remains intact, injection of therapeutic molecules such as growth factors, anabolic peptides (as an alternative to recombinant growth factors), or gene therapy (for prolonged delivery) to stimulate increased matrix synthesis is feasible. Supplementing the disk with more cells and/or scaffolds may be necessary in later stages of degeneration. However, a way to improve disk nutrition is essential. Maintaining disk height and improving the biological integrity of the intervertebral disk may lead to relief in pain. However, more research is needed to further establish the effects of these potential therapeutic agents on pain.

**Acknowledgments**

I thank AO Spine, Canadian Institute of Health Research (CIHR), and North American Spine Society (NASS). Dr. Ovidiu Ciobanu generated the figures.

**Disclosures**

Fackson Mwale, None

**References**

1. Luoma K, Riihimäki H, Luukkonen R, Raininko R, Viikari-Juntura E, Lamminen A. Low back pain in relation to lumbar disc degeneration. Spine (Phila Pa 1976) 2000;25:487–492
to the degenerated intervertebral disc. Biomaterials 2006;27:335–345
22 Thompson JP, Oegema TR Jr, Bradford DS. Stimulation of mature canine intervertebral disc by growth factors. Spine (Phil Pa 1976) 1991;16:253–260
23 Osada R, Ohshima H, Ishihara H, et al. Autocrine/paracrine mechanism of insulin-like growth factor-1 secretion, and the effect of insulin-like growth factor-1 on proteoglycan synthesis in bovine intervertebral discs. J Orthop Res 1996;14:690–699
24 Yoon ST, Patel NM. Molecular therapy of the intervertebral disc. Eur Spine J 2006;15(Suppl 3):S379–S388
25 Osada R, Ohshima H, Ishihara H, et al. Autocrine/paracrine mechanism of insulin-like growth factor-1 secretion, and the effect of insulin-like growth factor-1 on proteoglycan synthesis in bovine intervertebral discs. J Orthop Res 1996;14:690–699
26 Okuda S, Myou A, Ariga K, Nakase T, Yonenobu K, Yoshikawa H. Mechanisms of age-related decline in insulin-like growth factor-1 dependent proteoglycan synthesis in rat intervertebral disc cells. Spine (Phil Pa 1976) 2001;26:2421–2426
27 Gruber HE, Fisher EC Jr, Desai B, Stasky AA, Hoelscher G, Hanley EN Jr. Human intervertebral disc cells from the annulus: three-dimensional culture in agarose or alginate and responsiveness to TGF-beta1. Exp Cell Res 1997;235:13–21
28 Le Maître CL, Richardson SM, Baird P, Freemont AJ, Hoyland JA. Expression of receptors for putative anabolic growth factors in human intervertebral disc: implications for repair and regeneration of the disc. J Pathol 2005;207:445–452
29 Tsai TT, Guttapalli A, Oguz E, et al. Fibroblast growth factor-2 maintains the differentiation potential of nucleus pulposus cells in vitro: implications for cell-based transplantation therapy. Spine (Phil Pa 1976) 2007;32:495–502
30 Walsh AJ, Bradford DS, Lotz JC. In vivo growth factor treatment of degenerated intervertebral discs. Spine (Phil Pa 1976) 2004;29:156–163
31 Thompson JP, Oegema TR Jr, Bradford DS. Stimulation of mature canine intervertebral disc by growth factors. Spine (Phil Pa 1976) 1991;16:253–260
32 McCarthy PW, Carruthers B, Martin D, Pets P. Immunohistochemical demonstration of sensory nerve fibers and endings in lumbar intervertebral discs of the rat. Spine (Phil Pa 1976) 1991;16:653–655
33 Ashton IK, Walsh DA, Polak JM, Eisenstein SM. Substance P in intervertebral discs. Binding sites on vascular endothelium of the human annulus fibrosus. Acta Orthop Scand 1994;65:635–639
34 Gruber HE, Fisher EC Jr, Desai B, Stasky AA, Hoelscher G, Hanley EN Jr. Human intervertebral disc cells from the annulus: three-dimensional culture in agarose or alginate and responsiveness to TGF-beta1. Exp Cell Res 1997;235:13–21
35 Li J, Yoon ST, Hutton WC. Effect of bone morphogenetic protein-2 (BMP-2) on matrix production, other BMPs, and BMP receptors in rat intervertebral disc cells. J Spinal Disord Tech 2004;17:423–428
36 Nishida K, Kang JD, Gilbertson LC, et al. Modulation of the biologic activity of the rabbit intervertebral disc by gene therapy: an in vivo study of adenovirus-mediated transfer of the human transforming growth factor beta 1 encoding gene. Spine (Phil Pa 1976) 1999;24:2419–2425
37 Lee JY, Hall R, Pelinkovic D, et al. New use of a three-dimensional pellet culture system for human intervertebral disc cells: initial characterization and potential use for tissue engineering. Spine (Phil Pa 1976) 2001;26:2316–2322
38 Takae R, Matsunaga S, Origiuchi N, et al. Immunolocalization of bone morphogenetic protein and its receptors in degeneration of intervertebral disc. Spine (Phil Pa 1976) 1999;24:1397–1401
39 Kim DJ, Moon SH, Kim H, et al. Bone morphogenetic protein-2 facilitates expression of chondrogenic, not osteogenic, phenotype of human intervertebral disc cells. Spine (Phil Pa 1976) 2003;28:2679–2684
40 Haschtmann D, Ferguson SJ, Stoyanov JV. BMP-2 and TGF-β3 do not prevent spontaneous degeneration in rabbit disc explants but induce ossification of the annulus fibrosus. Eur Spine J 2012;21:1724–1733
41 Nakase T, Ariga K, Miyamoto S, et al. Distribution of genes for bone morphogenetic protein-4, -6, growth differentiation factor-5, and bone morphogenetic protein receptors in the process of experimental spondylosis in mice. J Neurolingu 2001;94(1, Suppl):68–75
42 Takegami K, Thonar EJ, An HS, Kamada H, Masuda K. Osteogenic protein-1 enhances matrix replenishment by intervertebral disc cells previously exposed to interleukin-1. Spine (Philad Pa 1976) 2002;27:1318–1325
43 Takegami K, An HS, Kumano F, et al. Osteogenic protein-1 is most effective in stimulating nucleus pulposus and annulus fibrosus cells to repair their matrix after chondroitinase ABC-induced in vitro chondrocytosis. Arthritis Res 2005;5:231–238
44 Miyamoto K, Masuda K, Kim JG, et al. Intradiscal injections of osteogenic protein-1 restore the viscoelastic properties of degenerated intervertebral disc tissue. Spine J 2006;6:692–703
45 Inmai Y, Okuma M, An HS, et al. Restoration of disc height loss by recombinant human osteogenic protein-1 injection into intervertebral discs undergoing degeneration induced by an intradiscal injection of chondroitinase ABC. Spine (Philad Pa 1976) 2007;32:1197–1205
46 Roughley PJ, Nguyen Q, Mort JS. Mechanisms of proteoglycan degradation in human articular cartilage. J Rheumatol Suppl 1991;27:52–54
47 Dean MF, Sansom P. Link peptide cartilage growth factor is degraded by membrane proteinases. Biochem J 2000;349(Pt 2):473–479
48 Liu H, McKenna LA, Dean MF. An N-terminal peptide from link protein can stimulate biosynthesis of collagen by human articular cartilage. Arch Biochem Biophys 2000;378:116–122
49 Liu H, McKenna LA, Dean M. An N-terminal peptide from link protein stimulates synthesis of cartilage proteoglycans. Biochem Soc Trans 1997;25:427S
50 McKenna LA, Liu H, Sansom PA, Dean MF. An N-terminal peptide from link protein stimulates proteoglycan biosynthesis in human articular cartilage in vitro. J Rheumatol Rheum 1998;145:157–162
51 Mwale F, Demers CN, Petit A, et al. A synthetic peptide of link protein stimulates the biosynthesis of collagens II, IX and proteoglycan by cells of the intervertebral disc. J Cell Biochem 2003;88:1202–1213
52 Petit A, Yao G, Rowas SA, et al. Effect of synthetic link N peptide on the expression of type I and type II collagens in human intervertebral disc cells. Tissue Eng Part A 2011;17:899–904
53 Mwale F, Masuda K, Pichika R, et al. The efficacy of Link N as a mediator of repair in a rabbit model of intervertebral disc degeneration. Arthritis Res Ther 2011;13:R120
54 Antoniou J, Wang HT, Alaseem AM, Haglund L, Roughley PJ, Mwale F. The effect of Link N on differentiation of human bone marrow–derived mesenchymal stem cells. Arthritis Res Ther 2012;14:R267
55 Wehling P, Schulitz KP, Robbins PD, Evans CH, Reinecke JA. Transfer of genes to chondrocytic cells of the lumbar spine. Proposal for a treatment strategy of spinal disorders by local gene therapy. Spine (Philad Pa 1976) 1997;22:1092–1097
56 Nishida K, Kang JD, Gilbertson LG, et al. Modulation of the biologic activity of the rabbit intervertebral disc by gene therapy: an in vivo study of adenovirus–mediated transfer of the human transforming growth factor beta 1 encoding gene. Spine (Philad Pa 1976) 1999;24:2419–2425
57 Paul R, Haydon RC, Cheng H, et al. Potential use of Sox9 gene therapy for intervertebral degenerative disc disease. Spine (Philad Pa 1976) 2003;28:755–763
58 Yoon ST, Park JS, Kim KS, et al. ISSLS prize winner: LMP-1 upregulates intervertebral disc cell production of proteoglycans and BMPs in vitro and in vivo. Spine (Philad Pa 1976) 2004;29:2603–2611
59 Wallach CJ, Sobajima S, Watanabe Y, et al. Gene transfer of the catabolic inhibitor TIMP-1 increases measured proteoglycans in cells from degenerated human intervertebral discs. Spine (Philad Pa 1976) 2003;28:2331–2337
60 Hiyama A, Sakai D, Tanaka M, et al. The relationship between the Wnt/β-catenin and TGF-β/BMP signals in the intervertebral disc cell. J Cell Physiol 2011;226:1139–1148
61 Hiyama A, Sakai D, Rishud MV, et al. Enhancement of intervertebral disc cell senescence by Wnt/β-catenin signaling-induced matrix metalloproteinase expression. Arthritis Rheum 2010;62:3036–3047
62 Kondo N, Yuasa T, Shimono K, et al. Intervertebral disc development is regulated by Wnt/β-catenin signaling. Spine (Philad Pa 1976) 2011;36:E513–E518
63 Church VL, Francis-West P. Wnt signalling during limb development. Int J Dev Biol 2002;46:927–936
64 Corm M. Wnt-beta-catenin signaling in the pathogenesis of osteoarthritis. Nat Clin Pract Rheumatol 2008;4:550–556
65 Nishita M, Hashimoto MK, Ogata S, et al. Interaction between Wnt and TGF-β/beta signalling pathways during formation of Spemann’s organizer. Nature 2000;403:781–785
66 Li X, Peng J, Wu M, et al. BMP2 promotes chondrocyte proliferation via the Wnt/β-catenin signaling pathway. Mol Med Rep 2011;4:621–626
67 McCarthy PW, Carruthers B, Martin D, Petts P. Immunohistochemical demonstration of sensory nerve fibers and endings in lumbar intervertebral discs of the rat. Spine (Philad Pa 1976) 1991;16:653–655
68 Freemont AJ, Peacock TE, Goupille P, Hoyland JA, O’Brien J, Jayson MI. Nerve ingrowth into diseased intervertebral disc in chronic back pain. Lancet 1997;350:178–181
69 Melrose J, Roberts S, Smith S, Menage J, Ghosh P. Increased nerve and blood vessel ingrowth associated with proteoglycan depletion in an ovine anular lesion model of experimental disc degeneration. Spine (Philad Pa 1976) 2002;27:1278–1285
70 Johnson WE, Caterson B, Eisenstein SM, Hynds DL, Snow DM, Roberts S. Human intervertebral disc aggrecan inhibits nerve growth in vitro. Arthritis Rheum 2002;46:2658–2664
71 Freemont AJ, Watkins A, Le Maitre C, et al. Nerve growth factor expression and innervation of the painful intervertebral disc. J Pathol 2002;197:286–292
72 Abe Y, Akeda K, An HS, et al. Proinflammatory cytokines stimulate the expression of nerve growth factor by human intervertebral disc cells. Spine (Philad Pa 2007) 32:635–642
73 Muleman D, Mammou S, Griffoul I, Watier H, Goupille P. Pathophysiology of disc-related sciatica. I.—Evidence supporting a chemical component. Joint Bone Spine 2006;73:158–158
74 Aoki Y, Rydevik B, Kikuchi S, Olmarker K. Local application of disc–blood vessel ingrowth associated with proteoglycan depletion in an ovine anular lesion model of experimental disc degeneration. Spine (Philad Pa 1976) 2003;28:2331–2342
75 Freemont AJ, Watkins A, Le Maitre C, et al. Nerve growth factor expression and innervation of the painful intervertebral disc. J Pathol 2002;197:286–292
76 Muleman D, Mammou S, Griffoul I, Watier H, Goupille P. Pathophysiology of disc-related sciatica. I.—Evidence supporting a chemical component. Joint Bone Spine 2006;73:151–151
77 Aoki Y, Rydevik B, Kikuchi S, Olmarker K. Local application of disc-related cytokines on spinal nerve roots. Spine (Philad Pa 1976) 2002;27:1614–1617
78 Cavanaugh JM. Neural mechanisms of lumbar pain. Spine (Philad Pa 1976) 1995;20:1804–1809
79 McLain RF. Mechanoreceptor endings in human cervical facet joints. Spine (Philad Pa 1976) 1994;19:495–501
80 Roberts S, Eisenstein SM, Menage J, Evans EH, Ashton IK. Mechanoreceptors in intervertebral discs. Morphology, distribution, and neuropeptides. Spine (Philad Pa 1976) 1995;20:2645–2651
81 Coppes MH, Marani E, Theomeer RT, Green GJ. Innervation of “painful” lumbar discs. Spine (Philad Pa 1976) 1997;22:2342–2349, discussion 2349–2350